|
Protara Therapeutics Inc (NASDAQ: TARA) |
|
Protara Therapeutics Inc
TARA's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Protara Therapeutics Inc's sales fell
in the fourth quarter of 2024 from the same quarter a year ago.
Biotechnology & Pharmaceuticals industry recorded
growth of revenues by 12.76 %
Protara Therapeutics Inc net loss increased from $-11 millions, to $-14 millions in fourth quarter of 2024,
• More on TARA's Growth
|
|
Protara Therapeutics Inc realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 0.51 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.17.
• More on TARA's Valuation
|
|
|
|
|
Protara Therapeutics Inc realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 0.51 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.17.
Protara Therapeutics Inc Price to Book Ratio is at 0.38 lower than Industry Avg. of 1869. and higher than S&P 500 Avg. of 0.01
• More on TARA's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com